What you should know:
– Time i GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, a once-daily oral PARP inhibitor for breast and pancreatic cancer patients. The study, entitled “Niraparib in the treatment of patients with advanced PALB2 mutated tumors” (PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022.
– The data-based design and site selection for this test were completed in less than 60 days, a rare achievement for a process that takes 8 months on average. This is due to Tempus’ TIME Trial program, a network of just-in-time providers that supports rapid patient identification, site activation, and clinical trial registration.
– The TIME Trial program uses real-time clinical and molecular data to match patients, largely in the community environment, with specific trials, and then accelerates the process of opening prequalified sites once identified. patients.